Strumento inattivo

Azioni Fresenius Kabi Oncology Ltd

Azioni

Prezzo di chiusura NSE India S.E. Altri mercati azionari
- ^INR	-

AstraZeneca sells rights to anaesthetics for up to $770 million	09/06/16
Fresenius SE KGaA : Kabi sells German oncology compounding business	16/02/15
Fresenius Kabi Oncology Ltd : India revokes GSK cancer drug patent in latest Big Pharma blow	02/08/13
Fresenius Kabi Oncology Ltd : India board revokes GSK patent on breast cancer drug Tykerb	02/08/13

Dirigenti	Titolo	Età	Da
Arvind Kumar Sharma CEO	Chief Executive Officer	-	01/07/18
Rahul Sharma DFI	Director of Finance/CFO	-	-
Maria Gobbi CHM	Chairman	-	13/11/14

Amministratori	Titolo	Età	Da
Michael Schönhofen BRD	Director/Board Member	63	11/08/08
Nikhil Kulshreshtha BRD	Director/Board Member	-	21/07/07
Maria Gobbi CHM	Chairman	-	13/11/14

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16,43%	122 Mrd
REGENERON PHARMACEUTICALS, INC.	+21,39%	116 Mrd
ARGENX SE	+22,18%	27,03 Mrd
BIONTECH SE	-21,37%	20,36 Mrd
GENMAB A/S	-16,89%	16,43 Mrd
BEIGENE, LTD.	-18,28%	15,91 Mrd
WUXI APPTEC CO., LTD.	-44,74%	15,6 Mrd
SAREPTA THERAPEUTICS, INC.	+61,89%	14,94 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,38%	13,59 Mrd